BOLT (Bolt Biotherapeutics, Inc.) חוב לטווח קצר להון

This daily price chart for Bolt Biotherapeutics (BOLT) reflects metrics where the value is 0.00. Bolt Biotherapeutics generates revenue by creating immunostimulatory antibodies for oncology centers, expecting profits from licensing payments and insurance procurement. Efficiency is increasing through AI-driven automation of molecule screening, while the expansion of its base is driven by a partnership with Pfizer and strict FDA safety regulations for therapy.

This ratio determines the proportion of liabilities maturing within one year relative to equity, serving as an indicator of current liquidity and credit risk. Analyzing the trend of short-term loans to equity allows for an assessment of the financial stability of Bolt Biotherapeutics (BOLT) during the recalibration of its R&D pipeline and the development of new antibody-conjugate platforms.